OcNOS® named the most complete NOS platform reviewed for the 2023 GigaOm Radar Reports, outperforming incumbent providers including Cisco and Juniper
SANTA CLARA, Calif., April 19, 2023 – IP Infusion, a leading provider of open network software and solutions for wireline and mobile network operators, today announced that GigaOm has, for the third consecutive year, designated IP Infusion a Leader, Outperformer and Platform player for all of its annual Network Operating System (NOS) Radar Reports. IP Infusion's OcNOS® platform is identified as the most complete of the more than 20 NOS vendors GigaOm analysts evaluated, outperforming incumbent providers including Cisco and Juniper.
GigaOm, a leading independent global provider of technology industry insights, developed the annual NOS Radar Reports to inform IT organizations about the varying strengths of competing solutions on the market. This year's analysis once again highlights IP Infusion's commanding market position as one of the most complete, mature and field-tested disaggregated platforms available.
For the third consecutive year, IP Infusion was ranked as a Leader/Outperformer, for NOS for Network Service Providers (NSPs), as well as a Leader/Outperformer in Cloud and Managed Service Providers, and Enterprise (Large and SMB) Network Operating Systems. IP Infusion was recognized as an Outperformer for its rapid customer adoption, strong execution against roadmap and vision compared to the competition over the previous 12 to 18 months.
OcNOS Platform's Robust Global Demand
GigaOm's assessment of IP Infusion as a rapidly growing market leader is underscored by IP Infusion's ever-increasing customer base:
- Over 500 customers, with more than 10,000 carrier-grade deployments
- Nearly 90 new customers in 2022, with 90 percent Year over Year USD sales increase
- Nearly 100 PartnerInfusion partners, with 28 added in 2022
IP Infusion's OcNOS platform includes the broadest range of use cases for Aggregation Router (AGGR), Cell Site Router (CSR), Data Center (DC), Routed Optical Networking (RON) and more. Strong global demand for its Aggregation Router, Cell Site Router and Data Center products has fueled continuing positive momentum throughout 2022 and into Q1 2023.
"IP Infusion's leadership position across all three market segments is testimony to its focused approach to delivering quality solutions meeting the demands of diverse use cases," said Ivan McPhee, GigaOm Analyst. "As a leading NOS for edge routing use cases, IP Infusion's OcNOS provides a viable alternative to legacy solutions, as indicated by its rapidly growing customer base."
"We are proud to be recognized by GigaOm as a leader and outperformer in its annual analysis of the three NOS market segments," said Atsushi Ogata, President and CEO, IP Infusion. "We appreciate the trust our customers put in our solution, and will continue to strive for providing the most reliable, full-featured open software platform that helps network operators to seamlessly integrate the best in open networking solutions."
Along with powerful customer demand, IP Infusion has also received significant industry renown in 2022. The Telecom Infra Project (TIP) recognized IP Infusion's OcNOS with its Validated Solution Gold Badge. IP Infusion also successfully demonstrated the maturity and stability of its OcNOS-based DCSG or Cell Site Router solution at the O-RAN Global PlugFest Spring 2022.
The GigaOm NOS Radar report noted that IP Infusion's unparalleled ability to migrate from existing and legacy services allows carriers to scale, reduce total cost of ownership, and gain digital transformation. Download a copy of the report, here.
Über IP Infusion
IP Infusion manufactures open network software and solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion is a market leader in Network Operating Systems. Our flagship software platform OcNOS® allows network operators to disaggregate their networks, streamline operations, and reduce Total Cost of Ownership (TCO). Network OEMs may also disaggregate network devices to expedite time to market, offer comprehensive services, and achieve carrier-grade robustness.
IP Infusion is headquartered in Santa Clara, Calif., and is a wholly owned and independently operated subsidiary of ACCESS CO., LTD. Additional information can be found at http://www.IPInfusion.com.
IP Infusion and OcNOS are trademarks or registered trademarks of IP Infusion. ACCESS is a registered trademark or trademark of ACCESS CO., LTD. in the United States, Japan and/or other countries. Northforge Innovations is a registered trademark of Northforge Innovations, Inc. All other trademarks, service marks, registered trademarks, or registered service marks mentioned are the property of their respective owners.
-end-
Pressekontakt
Katherine Verducci
1903 PR
kverducci@1903pr.com
408.429.5779
Über IP Infusion
IP Infusion ist ein führender Anbieter von Open-Networking-Software und liefert OcNOS, ein Carrier-Grade-Netzwerkbetriebssystem für Service Provider, Rechenzentren und AI-Fabric-Netze. Mit 26+ Jahren Netzwerkerfahrung und 600+ Operatoren weltweit ermöglicht IP Infusion offene, herstellerübergreifende, kosteneffiziente und flexible Netzwerkinfrastruktur auf validierter offener Hardware von Partnern wie Edgecore Networks, UfiSpace und Celestica. IP Infusion ist eine hundertprozentige Tochtergesellschaft der ACCESS CO., LTD. (Tokyo Stock Exchange: 4813).
Pressekontakt
For press inquiries, analyst briefings, or media materials, please unser Team kontaktieren or email pr@ipinfusion.com.
Zukunftsgerichtete Aussagen
Diese Mitteilung kann zukunftsgerichtete Aussagen zu Produkten, Technologien und Plänen von IP Infusion enthalten. Zukunftsgerichtete Aussagen beruhen auf den zum Veröffentlichungsdatum verfügbaren Informationen und sind mit Risiken und Unsicherheiten verbunden. Die tatsächlichen Ergebnisse können abweichen. Produktpläne, Funktionen, Release-Termine und Verfügbarkeit können sich ohne Vorankündigung ändern und stellen keine Zusage, kein Versprechen und keine rechtliche Verpflichtung dar. IP Infusion übernimmt keine Verpflichtung, zukunftsgerichtete Aussagen zu aktualisieren.